Should I buy or sell Sanofi stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sanofi in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" SNY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SNY, but not buy additional shares or sell existing shares. View SNY analyst ratings or view top-rated stocks .

What is Sanofi's stock price target for 2024?

6 brokerages have issued 1-year price targets for Sanofi's stock. Their SNY share price targets range from $55.00 to $55.00. On average, they expect the company's stock price to reach $55.00 in the next twelve months. This suggests a possible upside of 19.3% from the stock's current price. View analysts price targets for SNY or view top-rated stocks among Wall Street analysts .

How have SNY shares performed in 2024?

Sanofi's stock was trading at $49.73 on January 1st, 2024. Since then, SNY shares have decreased by 7.3% and is now trading at $46.11. View the best growth stocks for 2024 here .

When is Sanofi's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024. View our SNY earnings forecast .

How can I listen to Sanofi's earnings call?

Sanofi will be holding an earnings conference call on Thursday, April 25th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link .

How were Sanofi's earnings last quarter?

Sanofi (NASDAQ:SNY) announced its quarterly earnings data on Thursday, February, 1st. The company reported $0.89 EPS for the quarter, missing analysts' consensus estimates of $0.94 by $0.05. The company had revenue of $11.76 billion for the quarter, compared to analyst estimates of $13.02 billion. Sanofi had a net margin of 12.56% and a trailing twelve-month return on equity of 27.47%.

How often does Sanofi pay dividends? What is the dividend yield for Sanofi?

Sanofi declared an annual dividend on Tuesday, March 26th. Stockholders of record on Friday, May 10th will be given a dividend of $1.478 per share on Thursday, June 6th. This represents a yield of 2.98%. The ex-dividend date of this dividend is Thursday, May 9th. This is an increase from the stock's previous annual dividend of $1.38. Read our dividend analysis for SNY .

Is Sanofi a good dividend stock?

Sanofi (NASDAQ:SNY) pays an annual dividend of $1.38 per share and currently has a dividend yield of 3.00%. The company has been increasing its dividend for 2 consecutive year(s), indicating that it does not yet have a strong track record of dividend growth. The dividend payout ratio is 58.47%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, SNY will have a dividend payout ratio of 29.49% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for SNY .

What ETFs hold Sanofi's stock?

ETFs with the largest weight of Sanofi (NASDAQ:SNY) stock in their portfolio include VanEck Pharmaceutical ETF (PPH) , Subversive Mental Health ETF (SANE) , Pacer BioThreat Strategy ETF (VIRS) , Invesco International Dividend Achievers ETF (PID) , Putnam Focused Large Cap Value ETF (PVAL) , Amplify International Enhanced Dividend Income ETF (IDVO) , Fidelity Blue Chip Value ETF (FBCV) and Altrius Global Dividend ETF (DIVD) .

What is Paul Hudson's approval rating as Sanofi's CEO?

277 employees have rated Sanofi Chief Executive Officer Paul Hudson on Glassdoor.com . Paul Hudson has an approval rating of 94% among the company's employees. This puts Paul Hudson in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Sanofi own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sanofi investors own include AbbVie (ABBV) , Abbott Laboratories (ABT) , Adobe (ADBE) , Amgen (AMGN) , Broadcom (AVGO) , Boeing (BA) , Alibaba Group (BABA) , Bank of America (BAC) and BP (BP) .

Who are Sanofi's major shareholders?

Sanofi's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Foundation Resource Management Inc. (0.01%), CWM LLC (0.01%), First Hawaiian Bank (0.01%), Baker Ellis Asset Management LLC (0.00%), Thomasville National Bank (0.00%) and Cardinal Capital Management (0.00%). View institutional ownership trends .

How do I buy shares of Sanofi?

Shares of SNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Does Sanofi have any subsidiaries?

The following companies are subsidiares of Sanofi: A. Nattermann & Cie. GmbH, AO Sanofi Russia, Ablynx, Ablynx N.V., Allston Landing Limited Partnership, Aventis Inc., Aventis Pharma (Manufacturing) Pte. Ltd, Aventis Pharma Limited, Aventis Pharma S.A., Aventis S.A., Aventisub LLC, Bioverativ, Bioverativ Inc., Bioverativ Therapeutics Inc., Bioverativ U.S.LLC, Carraig Insurance DAC, Chattem Inc., Chinoin Private Co. Ltd, Francopia, Genfar S.A., Genzyme Corporation, Genzyme Europe B.V., Genzyme Flanders BVBA, Genzyme Global Sarl, Genzyme Ireland Limited, Genzyme Limited, Genzyme Polyclonals SAS, Genzyme Therapeutic Products Limited Partnership, Genzyme Therapeutics Limited, Genzyme de Argentina S.A., Hoechst GmbH, Kiadis Pharma, Limited Liability Company Sanofi-Aventis Ukraine, PT Aventis Pharma, Principia BioPharma, SSP Co. Ltd, Sanofi (Beijing) Pharmaceuticals Co.Ltd, Sanofi (China) Investment Co. Ltd, Sanofi (Hangzhou) Pharmaceuticals Co. Ltd, Sanofi A/S, Sanofi AB, Sanofi Arabia Trading Company Limited, Sanofi Aventis NA Holding Inc., Sanofi Belgium, Sanofi Biotechnology, Sanofi Chimie, Sanofi Egypt, Sanofi Finance Ireland limited, Sanofi Foreign Participations B.V., Sanofi Healthcare India Private Limited, Sanofi Ilac Sanayi ve Ticaret A.S., Sanofi India Limited, Sanofi K.K., Sanofi Mature IP, Sanofi Medley Farmaceutica Ltda, Sanofi Nichi-Iko K.K., Sanofi Oy, Sanofi Pasteur, Sanofi Pasteur Asi Ticaret A.S., Sanofi Pasteur Biologies Co. Ltd, Sanofi Pasteur Europe, Sanofi Pasteur Inc., Sanofi Pasteur India Private Ltd, Sanofi Pasteur Limited, Sanofi Pasteur Ltd, Sanofi Pasteur NVL, Sanofi Pasteur S.A. de C.V., Sanofi Produtos Farmaceuticos Lda, Sanofi Romania SRL, Sanofi S.p.A., Sanofi Saglik Urunleri Limited Sirketi, Sanofi Taiwan Co. Ltd, Sanofi US Corporation, Sanofi US Services Inc., Sanofi Vaccine Technologies, Sanofi Winthrop Industrie, Sanofi-Aventis (Malaysia) SDN. BHD., Sanofi-Aventis (Suisse) SA, Sanofi-Aventis (Thailand) Ltd, Sanofi-Aventis A.E.B.E., Sanofi-Aventis Algérie, Sanofi-Aventis Argentina S.A., Sanofi-Aventis Australia Pty Ltd, Sanofi-Aventis Canada Inc., Sanofi-Aventis Deutschland GmbH, Sanofi-Aventis France, Sanofi-Aventis GmbH, Sanofi-Aventis Groupe, Sanofi-Aventis Gulf FZE, Sanofi-Aventis Healthcare Pty Ltd, Sanofi-Aventis Hong-Kong Limited, Sanofi-Aventis Ireland Ltd, Sanofi-Aventis Israël Ltd, Sanofi-Aventis Korea Co. Ltd, Sanofi-Aventis Liban s.a.l., Sanofi-Aventis Maroc, Sanofi-Aventis Netherlands B.V., Sanofi-Aventis Norge AS, Sanofi-Aventis Pakistan Limited, Sanofi-Aventis Participations, Sanofi-Aventis Philippines Inc., Sanofi-Aventis Private Co Ltd, Sanofi-Aventis Recherche & Développement, Sanofi-Aventis S.A., Sanofi-Aventis Singapore Pte. Ltd, Sanofi-Aventis South Africa (Pty) Ltd, Sanofi-Aventis Sp. z.o.o., Sanofi-Aventis U.S. LLC, Sanofi-Aventis UK Holdings Limited, Sanofi-Aventis Winthrop S.A. de C.V., Sanofi-Aventis de Colombia S.A., Sanofi-Aventis de Mexico S.A. de C.V., Sanofi-Aventis de Panama S.A., Sanofi-Aventis de Venezuela S.A., Sanofi-Aventis del Ecuador S.A., Sanofi-Aventis del Peru S.A., Sanofi-Aventis s.r.o., Sanofi-Synthelabo (India) Private Ltd, Sanofi-aventis Vietnam Company Limited, Shenzhen Sanofi pasteur Biological Products Co Ltd, Synthorx, VaxServe Inc., sanofi-aventis Puerto Rico Inc, and sanofi-aventis Slovakia s.r.o.. Read More

NASDAQ:SNY

Sanofi (SNY) Stock Price, News & Analysis

→ Start loving Mondays like this (From DTI) (Ad)

Free SNY Stock Alerts

$46.11

+0.31 (+0.68%)

(As of 04/17/2024 ET)

Compare

Today's Range: $45.88
▼
$46.41
50-Day Range: $45.75
▼
$49.75
52-Week Range: $42.63
▼
$57.82

Volume: 3.71 million shs
Average Volume: 1.91 million shs
Market Capitalization: $116.64 billion

P/E Ratio: 19.54
Dividend Yield: 2.99%
Price Target: $55.00

Get Sanofi alerts:

Sanofi MarketRank™ Stock Analysis

Analyst Rating: Hold
2.17 Rating Score
Upside/Downside: 19.3% Upside
$55.00 Price Target
Short Interest: Healthy
0.16% of Float Sold Short
Dividend Strength: Moderate
Based on Four Factors
Sustainability: N/A
News Sentiment: 0.76
Based on 13 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 12.50%
From $4.16 to $4.68 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.20 out of 5 stars

Medical Sector

311th out of 913 stocks

Pharmaceutical Preparations Industry

130th out of 422 stocks

2.1

Analyst's Opinion

Consensus Rating
Sanofi has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on 2 buy ratings, 3 hold ratings, and 1 sell rating.
Amount of Analyst Coverage
Sanofi has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.16% of the float of Sanofi has been sold short.
Short Interest Ratio / Days to Cover
Sanofi has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Sanofi has recently decreased by 15.03%, indicating that investor sentiment is improving significantly.

2.5

Dividend Strength

Dividend Yield
Sanofi pays a meaningful dividend of 3.00%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
Sanofi has only been increasing its dividend for 2 years.
Dividend Coverage
The dividend payout ratio of Sanofi is 58.47%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Sanofi will have a dividend payout ratio of 29.49% next year. This indicates that Sanofi will be able to sustain or increase its dividend.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SNY.

3.2

News and Social Media Coverage

News Sentiment
Sanofi has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 13 news articles for Sanofi this week, compared to 7 articles on an average week.
Search Interest
Only 11 people have searched for SNY on MarketBeat in the last 30 days. This is a decrease of -35% compared to the previous 30 days.
MarketBeat Follows
16 people have added Sanofi to their MarketBeat watchlist in the last 30 days. This is an increase of 129% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Sanofi insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.00% of the stock of Sanofi is held by insiders.
Percentage Held by Institutions
Only 10.04% of the stock of Sanofi is held by institutions.

2.5

Earnings and Valuation

Earnings Growth
Earnings for Sanofi are expected to grow by 12.50% in the coming year, from $4.16 to $4.68 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Sanofi is 19.54, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 134.75.
Price to Earnings Ratio vs. Sector
The P/E ratio of Sanofi is 19.54, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 182.70.
Price to Earnings Growth Ratio
Sanofi has a PEG Ratio of 1.71. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Sanofi has a P/B Ratio of 1.45. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Start loving Mondays like this

Wouldn’t you love to start looking forward to Mondays? We’re in a New Paradigm Shift in the market that could make it possible! You see, rallies over the weekends have become much more common in the last few years. Imagine hitting a few buttons on your phone or laptop to place a quick trade before the weekend hits… And coming back on Monday to what could be extra income sitting in your account… Weekend after weekend!

Weekend after weekend!

About Sanofi Stock (NASDAQ:SNY)

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

SNY Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SNY Stock News Headlines

April 15, 2024 | marketbeat.com

Novo Nordisk Arms Wegovy to Be a Triple Threat (SNY)

Novo Nordisk has had success with Ozempic and Wegovy for Type 2 diabetes and obesity, seeks to expand indications to include cardio diseases and neuro disorders

April 18, 2024 | americanbankingnews.com

Brokers Issue Forecasts for Sanofi's Q1 2024 Earnings (NASDAQ:SNY)

April 18, 2024 | DTI (Ad)

Don’t expose yourself to stocks during the week

The S&P 500 just crossed below the 200 day moving average… The Nasdaq is bleeding out… Are we headed for a recession?! If you’ve been in the stock market the last few months, it hasn’t been fun… But what if I told you there was a way to target “BONUS” income just by doing a unique type of trade over the weekend? When the markets are closed. And volatility is minimal.

April 18, 2024 | americanbankingnews.com

Sanofi (SNY) Set to Announce Quarterly Earnings on Thursday

April 17, 2024 | benzinga.com

Novartis Multiple Sclerosis Drug Kesimpta Shows Substantial Benefit Of Up To 6 Years

April 17, 2024 | businesswire.com

COTA Announces Strategic Collaboration with Sanofi to Leverage Real-World Data and AI to Accelerate Cancer Trials

April 17, 2024 | finanznachrichten.de

Sanofi - Aventis Groupe: Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis

April 16, 2024 | americanbankingnews.com

Sanofi (NASDAQ:SNY) Given Consensus Rating of "Hold" by Analysts

April 18, 2024 | DTI (Ad)

Don’t expose yourself to stocks during the week

April 11, 2024 | msn.com

Regeneron hits three-month low after DOJ complaint; RBC defends

April 11, 2024 | bizjournals.com

Sanofi to shutter operations at Peninsula drug maker it bought less than 3 years ago

April 9, 2024 | msn.com

Nurix gains after extending Sanofi research pact

April 9, 2024 | barrons.com

Meet Europe's Mag 18. Novo Nordisk Stock, ASML, and Others Can Rival the Mag Seven.

April 8, 2024 | globenewswire.com

Sanofi - AGM 30.04.2024 - Availability of Preparatory documents

April 8, 2024 | investorplace.com

Sanofi Layoffs 2024: What to Know About the Latest SNY Job Cuts

April 5, 2024 | investing.com

Sanofi shares target cut amid FDA Dupixent review

April 5, 2024 | businesswire.com

Sanofi Announces Launch of Verorab® (Sanofi Inactivated Rabies Vaccine) in the UK for Pre-exposure and Post-exposure Prophylaxis of Rabies in All Age Groups

April 4, 2024 | finanznachrichten.de

Diabetes Drug Lixisenatide May Slow Down Parkinson's: Study

April 4, 2024 | msn.com

Sanofi to Resolve 4,000 Zantac Cancer Lawsuits in US Courts

April 4, 2024 | benzinga.com

In Heart Burn Drug Zantac's Litigation Saga, Sanofi Nears Settlement in Major Lawsuit Cluster

April 4, 2024 | cnbc.com

Diabetes drug similar to Ozempic helped slow progression of Parkinson's disease in small trial

April 4, 2024 | msn.com

Diabetes medication appears to slow progress of Parkinson’s disease in French-backed trial

April 3, 2024 | msn.com

Sanofi to Settle About 4,000 Suits Over Zantac Cancer Claims

April 3, 2024 | reuters.com

Sanofi to settle 4,000 Zantac cancer lawsuits in US state courts

April 3, 2024 | finance.yahoo.com

Sanofi: BUY as FDA reviews Dupixent for COPD

April 1, 2024 | nasdaq.com

SNY Quantitative Stock Analysis

March 30, 2024 | seekingalpha.com

Xeris Biopharma: Checking-In On One Of My 'Top Ideas'

See More Headlines

Receive SNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sanofi and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/01/2024
Today: 4/18/2024
Next Earnings (Confirmed): 4/25/2024
Ex-Dividend for 6/6 Dividend: 5/09/2024
Dividend Payable: 6/06/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:SNY
CUSIP: N/A
CIK: 1121404
Web: www.sanofi.com
Phone: (315) 377-4000
Fax: 33-1-53-77-43-03
Employees: 86,088
Year Founded: 2004

Price Target and Rating

Average Stock Price Target: $55.00
High Stock Price Target: $55.00
Low Stock Price Target: $55.00
Potential Upside/Downside: +19.3%
Consensus Rating: Hold
Rating Score (0-4): 2.17
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): $2.36
Trailing P/E Ratio: 19.54
Forward P/E Ratio: 11.08
P/E Growth: 1.71
Net Income: $5.84 billion
Net Margins: 12.56%
Pretax Margin: 15.40%
Return on Equity: 27.47%
Return on Assets: 16.07%

Debt

Debt-to-Equity Ratio: 0.19
Current Ratio: 1.27
Quick Ratio: 0.87

Sales & Book Value

Annual Sales: $46.61 billion
Price / Sales: 2.50
Cash Flow: $6.44 per share
Price / Cash Flow: 7.16
Book Value: $31.81 per share
Price / Book: 1.45

Miscellaneous

Outstanding Shares: 2,529,610,000
Free Float: 2,504,311,000
Market Cap: $116.64 billion
Optionable: Optionable
Beta: 0.61

Social Links

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Mr. Paul Hudson (Age 57)
CEO & Director
Comp: $4.07M
Mr. François-Xavier Roger (Age 62)
Chief Financial Officer
Ms. Madeleine Roach (Age 40)
Executive VP & Head of Business Operations
Mr. Laurent Gilhodes
Principal Accounting Officer and Vice President of Corporate Accounting
Dr. Josephine Fubara
Chief Science Officer of Consumer Health Care
Eva Schaefer-Jansen
Head of Investor Relations
Mr. Dante Beccaria
Global Compliance Officer & VP
Mr. Roy Papatheodorou (Age 46)
Executive VP & General Counsel
Mr. Josep Catlla
Head of Communications
Mr. Pierre Chancel (Age 67)
Senior Vice President of Global Diabetes and Senior Vice President of Global Marketing

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

Should I Buy Sanofi Stock? SNY Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Sanofi:

Sanofi has a diverse portfolio of specialty care products, including DUPIXENT, which has shown promising results in treating various health conditions.
The company is actively engaged in research and development collaborations to develop novel small molecules for oncology and immunology, indicating a focus on innovation and future growth.
Sanofi's collaboration with various biotech companies for the development of antibody-based therapies and genome editing technologies showcases a commitment to staying at the forefront of healthcare advancements.
With a net margin of 12.56% and a return on equity of 27.47%, Sanofi demonstrates strong financial performance and efficiency in utilizing shareholder equity.
Analysts predict a positive EPS for the current year, indicating potential profitability and growth for investors.

Cons

Investors should be bearish about investing in Sanofi for these reasons:

Sanofi has received mixed analyst ratings recently, with downgrades from several firms, potentially signaling uncertainties or challenges in the company's performance or outlook.
The average rating of "Hold" and a consensus target price of $57.50 suggest a lack of strong buy recommendations, which may indicate limited short-term growth potential.
Market sentiment towards Sanofi may be impacted by the downgrade from "strong-buy" to "buy" by StockNews.com, potentially affecting investor confidence in the company's future prospects.
The company's stock price fluctuations and analyst rating changes could introduce volatility and uncertainty for investors, requiring a cautious approach to investment decisions.
Investors should closely monitor any further developments or news related to Sanofi to make informed decisions based on the evolving market landscape and industry dynamics.

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, April 10, 2024. Please send any questions or comments about these Sanofi pros and cons to contact@marketbeat.com.

SNY Stock Analysis - Frequently Asked Questions

Should I buy or sell Sanofi stock right now?: 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sanofi in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" SNY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SNY, but not buy additional shares or sell existing shares.
View SNY analyst ratings or view top-rated stocks.
What is Sanofi's stock price target for 2024?: 6 brokerages have issued 1-year price targets for Sanofi's stock. Their SNY share price targets range from $55.00 to $55.00. On average, they expect the company's stock price to reach $55.00 in the next twelve months. This suggests a possible upside of 19.3% from the stock's current price.
View analysts price targets for SNY or view top-rated stocks among Wall Street analysts.
How have SNY shares performed in 2024?: Sanofi's stock was trading at $49.73 on January 1st, 2024. Since then, SNY shares have decreased by 7.3% and is now trading at $46.11.
View the best growth stocks for 2024 here.
When is Sanofi's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024.
View our SNY earnings forecast.
How can I listen to Sanofi's earnings call?: Sanofi will be holding an earnings conference call on Thursday, April 25th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.
How were Sanofi's earnings last quarter?: Sanofi (NASDAQ:SNY) announced its quarterly earnings data on Thursday, February, 1st. The company reported $0.89 EPS for the quarter, missing analysts' consensus estimates of $0.94 by $0.05. The company had revenue of $11.76 billion for the quarter, compared to analyst estimates of $13.02 billion. Sanofi had a net margin of 12.56% and a trailing twelve-month return on equity of 27.47%.
How often does Sanofi pay dividends? What is the dividend yield for Sanofi?: Sanofi declared an annual dividend on Tuesday, March 26th. Stockholders of record on Friday, May 10th will be given a dividend of $1.478 per share on Thursday, June 6th. This represents a yield of 2.98%. The ex-dividend date of this dividend is Thursday, May 9th. This is an increase from the stock's previous annual dividend of $1.38.
Read our dividend analysis for SNY.
Is Sanofi a good dividend stock?: Sanofi (NASDAQ:SNY) pays an annual dividend of $1.38 per share and currently has a dividend yield of 3.00%. The company has been increasing its dividend for 2 consecutive year(s), indicating that it does not yet have a strong track record of dividend growth. The dividend payout ratio is 58.47%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, SNY will have a dividend payout ratio of 29.49% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for SNY.

What ETFs hold Sanofi's stock?: ETFs with the largest weight of Sanofi (NASDAQ:SNY) stock in their portfolio include VanEck Pharmaceutical ETF (PPH), Subversive Mental Health ETF (SANE), Pacer BioThreat Strategy ETF (VIRS), Invesco International Dividend Achievers ETF (PID), Putnam Focused Large Cap Value ETF (PVAL), Amplify International Enhanced Dividend Income ETF (IDVO), Fidelity Blue Chip Value ETF (FBCV) and Altrius Global Dividend ETF (DIVD).
What is Paul Hudson's approval rating as Sanofi's CEO?: 277 employees have rated Sanofi Chief Executive Officer Paul Hudson on Glassdoor.com. Paul Hudson has an approval rating of 94% among the company's employees. This puts Paul Hudson in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Sanofi own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Sanofi investors own include AbbVie (ABBV), Abbott Laboratories (ABT), Adobe (ADBE), Amgen (AMGN), Broadcom (AVGO), Boeing (BA), Alibaba Group (BABA), Bank of America (BAC) and BP (BP).
Who are Sanofi's major shareholders?: Sanofi's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Foundation Resource Management Inc. (0.01%), CWM LLC (0.01%), First Hawaiian Bank (0.01%), Baker Ellis Asset Management LLC (0.00%), Thomasville National Bank (0.00%) and Cardinal Capital Management (0.00%).
View institutional ownership trends.
How do I buy shares of Sanofi?: Shares of SNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.
Does Sanofi have any subsidiaries?: The following companies are subsidiares of Sanofi: A. Nattermann & Cie. GmbH, AO Sanofi Russia, Ablynx, Ablynx N.V., Allston Landing Limited Partnership, Aventis Inc., Aventis Pharma (Manufacturing) Pte. Ltd, Aventis Pharma Limited, Aventis Pharma S.A., Aventis S.A., Aventisub LLC, Bioverativ, Bioverativ Inc., Bioverativ Therapeutics Inc., Bioverativ U.S.LLC, Carraig Insurance DAC, Chattem Inc., Chinoin Private Co. Ltd, Francopia, Genfar S.A., Genzyme Corporation, Genzyme Europe B.V., Genzyme Flanders BVBA, Genzyme Global Sarl, Genzyme Ireland Limited, Genzyme Limited, Genzyme Polyclonals SAS, Genzyme Therapeutic Products Limited Partnership, Genzyme Therapeutics Limited, Genzyme de Argentina S.A., Hoechst GmbH, Kiadis Pharma, Limited Liability Company Sanofi-Aventis Ukraine, PT Aventis Pharma, Principia BioPharma, SSP Co. Ltd, Sanofi (Beijing) Pharmaceuticals Co.Ltd, Sanofi (China) Investment Co. Ltd, Sanofi (Hangzhou) Pharmaceuticals Co. Ltd, Sanofi A/S, Sanofi AB, Sanofi Arabia Trading Company Limited, Sanofi Aventis NA Holding Inc., Sanofi Belgium, Sanofi Biotechnology, Sanofi Chimie, Sanofi Egypt, Sanofi Finance Ireland limited, Sanofi Foreign Participations B.V., Sanofi Healthcare India Private Limited, Sanofi Ilac Sanayi ve Ticaret A.S., Sanofi India Limited, Sanofi K.K., Sanofi Mature IP, Sanofi Medley Farmaceutica Ltda, Sanofi Nichi-Iko K.K., Sanofi Oy, Sanofi Pasteur, Sanofi Pasteur Asi Ticaret A.S., Sanofi Pasteur Biologies Co. Ltd, Sanofi Pasteur Europe, Sanofi Pasteur Inc., Sanofi Pasteur India Private Ltd, Sanofi Pasteur Limited, Sanofi Pasteur Ltd, Sanofi Pasteur NVL, Sanofi Pasteur S.A. de C.V., Sanofi Produtos Farmaceuticos Lda, Sanofi Romania SRL, Sanofi S.p.A., Sanofi Saglik Urunleri Limited Sirketi, Sanofi Taiwan Co. Ltd, Sanofi US Corporation, Sanofi US Services Inc., Sanofi Vaccine Technologies, Sanofi Winthrop Industrie, Sanofi-Aventis (Malaysia) SDN. BHD., Sanofi-Aventis (Suisse) SA, Sanofi-Aventis (Thailand) Ltd, Sanofi-Aventis A.E.B.E., Sanofi-Aventis Algérie, Sanofi-Aventis Argentina S.A., Sanofi-Aventis Australia Pty Ltd, Sanofi-Aventis Canada Inc., Sanofi-Aventis Deutschland GmbH, Sanofi-Aventis France, Sanofi-Aventis GmbH, Sanofi-Aventis Groupe, Sanofi-Aventis Gulf FZE, Sanofi-Aventis Healthcare Pty Ltd, Sanofi-Aventis Hong-Kong Limited, Sanofi-Aventis Ireland Ltd, Sanofi-Aventis Israël Ltd, Sanofi-Aventis Korea Co. Ltd, Sanofi-Aventis Liban s.a.l., Sanofi-Aventis Maroc, Sanofi-Aventis Netherlands B.V., Sanofi-Aventis Norge AS, Sanofi-Aventis Pakistan Limited, Sanofi-Aventis Participations, Sanofi-Aventis Philippines Inc., Sanofi-Aventis Private Co Ltd, Sanofi-Aventis Recherche & Développement, Sanofi-Aventis S.A., Sanofi-Aventis Singapore Pte. Ltd, Sanofi-Aventis South Africa (Pty) Ltd, Sanofi-Aventis Sp. z.o.o., Sanofi-Aventis U.S. LLC, Sanofi-Aventis UK Holdings Limited, Sanofi-Aventis Winthrop S.A. de C.V., Sanofi-Aventis de Colombia S.A., Sanofi-Aventis de Mexico S.A. de C.V., Sanofi-Aventis de Panama S.A., Sanofi-Aventis de Venezuela S.A., Sanofi-Aventis del Ecuador S.A., Sanofi-Aventis del Peru S.A., Sanofi-Aventis s.r.o., Sanofi-Synthelabo (India) Private Ltd, Sanofi-aventis Vietnam Company Limited, Shenzhen Sanofi pasteur Biological Products Co Ltd, Synthorx, VaxServe Inc., sanofi-aventis Puerto Rico Inc, and sanofi-aventis Slovakia s.r.o..
Read More

This page (NASDAQ:SNY) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial